4930-99-8

Usage

Uses

Used in Organic Synthesis:
(3-METHYL-PYRIDIN-2-YL)-HYDRAZINE is utilized as a building block for the synthesis of various organic compounds, leveraging its reactive functional groups to form a wide array of chemical products. Its presence in these syntheses contributes to the creation of new molecules with potential applications across different industries.
Used in Pharmaceutical Research:
In the pharmaceutical industry, (3-METHYL-PYRIDIN-2-YL)-HYDRAZINE is employed as a precursor in the development of new pharmaceuticals. Its unique structure allows for the exploration of novel drug candidates, potentially leading to the discovery of treatments for various diseases and conditions.
Used in Chemical Research:
(3-METHYL-PYRIDIN-2-YL)-HYDRAZINE serves as a valuable tool in chemical research, where its properties and reactivity are studied to understand and advance the field of chemistry. Its participation in various chemical reactions provides insights into reaction mechanisms and the behavior of similar compounds.
Used in Biological Research:
In biological research, (3-METHYL-PYRIDIN-2-YL)-HYDRAZINE may be used to study its interactions with biological systems, offering potential insights into its biological activity and possible applications in medicine and biology. Its unique structure could provide new avenues for understanding biochemical processes and developing new therapeutic strategies.

InChI:InChI=1/C6H9N3/c1-5-3-2-4-8-6(5)9-7/h2-4H,7H2,1H3,(H,8,9)

Upstream product

• 2369-18-8 2-fluoro-3-methylpyridine 
• 18368-76-8 2 chloro-3-methylpyridine 
• 3430-17-9 2-bromo-3-picoline 

Downstream Products

• 4926-20-9 8-methyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one 
• 1610952-09-4 3-(1-(4-chlorophenyl)cyclopropyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridine 

Relevant academic research and scientific papers

Tetrahydroindazole inhibitors of CDK2/cyclin complexes

Over 50 tetrahydroindazoles were synthesized after 7-bromo-3,6,6-trimethyl-1-(pyridin-2-yl)-5,6,7,7a-tetrahydro-1H-indazol-4(3aH)-one (3) was identified as a hit compound in a high throughput screen for inhibition of CDK2 in complex with cyclin A. The activity of the most promising analogues was evaluated by inhibition of CDK2 enzyme complexes with various cyclins. Analogues 53 and 59 showed 3-fold better binding affinity for CDK2 and 2- to 10-fold improved inhibitory activity against CDK2/cyclin A1, E, and O compared to screening hit 3. The data from the enzyme and binding assays indicate that the binding of the analogues to a CDK2/cyclin complex is favored over binding to free CDK2. Computational analysis was used to predict a potential binding site at the CDK2/cyclin E1 interface.

PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS

Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT 1. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, R4, R5, and G, are defined herein.

Catalytic Coupling between Unactivated Aliphatic C-H Bonds and Alkynes via a Metal-Hydride Pathway

We report a Rh(I)-catalyzed site-selective coupling between ketone β-C(sp3)-H bonds and aliphatic alkynes using an in situ-installed directing group. Upon hydrogenation or hydration, various β-alkylation or β-aldol products of the ketones are obtained with broad functional group tolerance. Mechanistic investigations support the involvement of a Rh-H intermediate through oxidative addition of Rh(I) into the β-C-H bonds. Thus, to the best of our knowledge, this transformation represents the first example of catalytic couplings between unsaturated hydrocarbons and unactivated aliphatic C-H bonds via a metal-hydride pathway.

AMINO-SUBSTITUTED HETEROCYCLIC DERIVATIVES AS SODIUM CHANNEL INHIBITORS

The present invention relates to novel aminoindazolyl derivative compounds of Formula(I), the use of said compounds in treating diseases mediated by modulation of voltage-gated sodium channels in particular Nav1.7 AND to compositions containing said derivatives.

Condensed pyrazole derivatives, process for producing the same and use thereof

Novel pharmaceutical compositions for inhibiting Th2-selective immune response and pharmaceutical compositions for inhibiting cyclooxygenase comprising condensed pyrazole derivatives represented by the general formula (I): or salts thereof.